Gilead Sciences

December 13, 2016

Galapagos Begins Phase 2b/3 Clinical Trial of Filgotinib in Ulcerative Colitis Patients

News

Galapagos NV recently announced that it has dosed the first patient with ulcerative colitis (UC) in its SELECTION Phase 2b/3 clinical trial, investigating the efficacy and safety of two doses ... Read more

October 4, 2016

Galapagos Readies Two Clinical Trials To Advance Filgotinib as IBD Treatment

News

Galapagos has completed discussions with U.S. and European regulatory authorities to begin the DIVERSITY Phase 3 clinical trial (NCT02914561) in patients with Crohn’s disease and the SELECTION Phase 2b/3 study (NCT02914522) in ... Read more

October 3, 2016

Key Findings on Filgotinib Trial for Crohn’s to be Presented at UEG Week

News

Galapagos will present endoscopic improvements and other key findings from the FITZROY Phase 2 clinical trial of filgotinib in Crohn’s disease, during United European Gastroenterology Week (UEG Week), Oct. 15-19, in Vienna. ... Read more

April 28, 2016April 28, 2016

New Clinical Trial Data on Crohn’s Disease Treatment Filgotinib Reported by Galapagos

News

Beglium-based Galapagos NV recently reported additional data from its Phase 2 FITZROY clinical trial assessing filgotinib, a selective JAK1 inhibitor being investigated for the treatment of Crohn’s disease. The FITZROY trial assessed the efficacy and ... Read more